《抗肿瘤药物暴露防护管理指南》解读

Interpretation of management guidelines for preventing exposure to antineoplastics

抗肿瘤药物暴露是一种潜在的健康威胁,若处置不当也会造成环境污染,是一个值得关注的医疗安全问题。为提高接触抗肿瘤药物人员(医务人员、药物运输人员、患者及其照护人员等)的暴露防护意识,规范暴露防护操作,减少暴露风险和损伤,中国药理学会治疗药物监测研究专业委员会、中国药学会医院药学专业委员会、中华医学会肿瘤学分会、中国医疗保健国际交流促进会护理分会、中国药理学会药源性疾病学专业委员会共同制订了《抗肿瘤药物暴露防护管理指南》,并发表在Chinese Journal of Cancer Research杂志2023年第1期。该指南参考世界卫生组织指南制订手册等国际方法学规范进行制订,围绕抗肿瘤药物在医疗机构的全流程管理,采用德尔菲法确定临床问题并形成了14条推荐意见。本文就14条推荐意见进行解读,希望有助于推进该指南的实施。

Exposure to antineoplastics is a potential health threat.If improperly disposed,it will also cause environmental pollution,which is a medical safety issue worthy of attention.In order to improve the protection awareness of healthcare professionals exposed to antineoplastic drugs(medical personnels,drug transportation staffs,patients and their caregivers,etc.),standardize exposure protection operations,and reduce the risk and harm of occupational exposure,the Division of Therapeutic Drug Monitoring of Chinese Pharmacological Society,the Hospital Pharmacy Professional Committee of Chinese Pharmaceutical Association,the Oncology Society of Chinese Medical Association,the Nursing Branch of China International Exchange and Promotive Association for Medical and Healthcare,and Chinese Pharmacological Society Professional Committee of Drug-induced Diseases formulated the Management guidelines for preventing exposure to antineoplastics,which was published in the 1st issue of Chinese Journal of Cancer Research in 2023.The guideline was developed referring to the World Health Organization handbook for guideline development and other international methodologies and focused on the full-process management of antineoplastics in hospitals.Using the Delphi method,clinical questions and 14 recommendations were formulated.This paper interprets 14 recommendations,hoping to help promote the implementation of the guideline.